Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aimovig Clear all
Terminated Phase 2 Interventional Results available

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

NCT05142228
View directory record Official record
Conditions
Trigeminal Neuropathy
Interventions
Erenumab-Aooe, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Sep 30, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750
View directory record Official record
Conditions
Migraine, Episodic Migraine, Chronic Migraine, Headache
Interventions
CGRP antibody or gepant
Drug
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 30, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

NCT05684692
View directory record Official record
Conditions
Schwannomatosis, Schwannomas, Pain, Chronic
Interventions
Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 4 Interventional

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

NCT06173661
View directory record Official record
Conditions
Migraine, Menstrual Migraine, Menstrually Related Migraine
Interventions
Fremanezumab, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 30, 2026, 5:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

NCT04547179
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab-Vfrm, BLAfit®, Saline
Drug · Device · Other
Lead sponsor
Manhattan Beach Orthodontics
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Sep 30, 2026, 5:03 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 30, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

NCT03912337
View directory record Official record
Conditions
Migraine
Interventions
Placebo, Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

NCT02483585
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

NCT03927144
View directory record Official record
Conditions
Episodic Migraine
Interventions
AMG334, Oral Prophylactic
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Sep 30, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Erenumab For Treatment of Hemicrania Continua

NCT04303845
View directory record Official record
Conditions
Hemicrania Continua
Interventions
Erenumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 66 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Sep 30, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

Emgality for Migraine in Breastmilk

NCT06085144
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

NCT04098250
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Erenumab, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 30, 2026, 5:03 AM EDT
Completed No phase listed Observational

Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data

NCT05177406
View directory record Official record
Conditions
Migraine
Interventions
Aimovig
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

NCT02066415
View directory record Official record
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
34
States / cities
La Jolla, California • Newport Beach, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

NCT04179474
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Erenumab, Galcanezumab
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Springfield, Missouri • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

NCT04252742
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 30, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

NCT05049057
View directory record Official record
Conditions
Posttraumatic Headache, Mild Traumatic Brain Injury
Interventions
Erenumab 140 Mg/mL Subcutaneous Solution, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Fort Bragg, North Carolina • Pittsburgh, Pennsylvania • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 30, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

NCT04461795
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
Drug
Lead sponsor
David True
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
City of Saint Peters, Missouri • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 30, 2026, 5:03 AM EDT